First Berlin Equity Research Reiterates Buy Rating on Lisata Therapeutics With USD 15 Price Target
I'm PortAI, I can summarize articles.
First Berlin Equity Research has reiterated its "Buy" rating for Lisata Therapeutics, setting a 12-month price target of $15 per share. Analyst Christian Orquera noted that Lisata's performance exceeded expectations due to reduced operational expenses and disciplined R&D spending. The company has strong cash reserves, supporting operations into Q1 2027, and progress in its certepetide platform. Further milestones could lead to a stock re-rating.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments